Trading November 13, 2026

Terumo shares slide after first-half results and guidance cut

Terumo shares slide after first-half results and guidance cut
Terumomedical devicesearningsguidance cutJapan stocksimpairmentrecall

Terumo shares dropped 6.2% to ¥2,399.5 on Friday, following first-half fiscal 2026 results released the previous evening that combined record adjusted profit with a sharp fall in reported earnings and a significant cut to full-year guidance.

For the six months ended September 30, 2026, reported operating profit fell 30% to ¥70.8 billion, dragged down by ¥76.4 billion in impairment losses and charges tied mainly to ending the CSL Plasma supply agreement. Terumo also reduced full-year operating profit guidance by ¥41 billion to ¥119 billion and lowered its net profit forecast to ¥87.5 billion from ¥120 billion, a cut of about 27%.

In a further setback, Terumo said a voluntary recall and shipment suspension at its Terumo Aortic unit is expected to trim full-year revenue by about ¥8 billion and operating profit by ¥41 billion, including an estimated ¥38 billion of risks related to Aortic asset values that have not yet been fully determined.

The selloff came despite a generally supportive backdrop for Japanese equities, with the Nikkei 225 gaining as much as 1.5% as it rebounded from losses through October and early November.

This article was produced with AI assistance and reviewed by an editor. For more information, see our terms and conditions.

FractLab Unlock Your Edge A proprietary strategy built to surface hidden opportunities others miss. FractLab Trade with FractLab Multi-timeframe trend detection, accumulation filters and adaptive position scaling. FractLab Try it with a guarantee Full TradingView toolkit access. 30-day money back if it is not for you. Try